Palylyk-Colwell E, McGahan L
Issues Emerg Health Technol. 2006 Sep(89):1-4.
(1) Rituximab (RTX), a monoclonal antibody, selectively targets CD20+ B-cells that are implicated in the pathogenesis of rheumatoid arthritis (RA). (2) The use of RTX with methotrexate (MTX) results in statistically significant clinical improvements among RA patients who have an inadequate response to standard therapies, when compared to the use of MTX alone. (3) The optimal dose, duration of treatment or retreatment, long-term efficacy and safety, and placement of RTX in RA treatment algorithms need to be further investigated. (4) Health Canada has approved the combination of RTX with MTX for use in adult patients with moderate to severe active RA, who have had an inadequate response or intolerance to >1 tumour necrosis factor (TNF) inhibitor therapies.
（1）利妥昔单抗（RTX）是一种单克隆抗体，可选择性靶向参与类风湿关节炎（RA）发病机制的CD20+B细胞。（2）与单独使用甲氨蝶呤（MTX）相比，RTX与MTX联合使用可使对标准疗法反应不佳的RA患者在临床上有统计学意义的显著改善。（3）RTX的最佳剂量、治疗或再治疗持续时间、长期疗效和安全性，以及RTX在RA治疗方案中的地位，都需要进一步研究。（4）加拿大卫生部已批准RTX与MTX联合用于中度至重度活动性RA成年患者，这些患者对一种以上肿瘤坏死因子（TNF）抑制剂疗法反应不佳或不耐受。
